23/02/2026 - Approval of the board of directors guidelines and appointment of the investor relations director

Pisa, 23rdFebruary 2026 - The Board of Directors of Pharmanutra S.p.A. (MTA; Ticker: PHN), in line with the Recommendations of the Corporate Governance Code and in view of the renewal of the administrative body, upon the proposal of the Remuneration and Appointments Committee, today approved the "Guidelines of the Board of Directors of Pharmanutra S.p.A. to shareholders on the future size and composition of the new Board of Directors". The document is available to the public on the Company's website at https://pharmanutragroup.com/governance/company-documents.

In line with the recommendations of the Corporate Governance Code, the guidelines of the outgoing Board of Directors are being released prior to the publication of the notice of call of the Shareholders' Meeting and the Meeting documentation, in order to facilitate shareholders in view of the Shareholders' Meeting scheduled on April 27th, 2026 as per the Company's financial calendar.

The Board of Directors also announces the appointment of Simona Del Re as the Company's Investor Relations Director, effective today. A graduate in Business Administration at Luigi Bocconi University in Milan, Simona Del Re has held positions of increasing responsibility in international companies, including Gucci, The Lane Crawford Joyce Group, Asian leader in luxury retail based in Hong Kong, and Perini Navi. Subsequently, she served as Investor Relations & ESG Director at The Italian Sea Group.

Founded in 2003 in Pisa by Andrea and Roberto Lacorte, Pharmanutra is the holding company of an international Group engaged in the research, development, and commercialization of nutritional supplements, medical devices, and patented raw materials. A leader in iron-based supplements through its Sucrosomial® Technology (SiderAL® and Apportal®), and an emerging player in medical devices for mobility (Cetilar®), the Group internally manages the entire value chain and holds a solid portfolio of patents, brands, and clinical evidence.

Pharmanutra operates in over 80 countries, with subsidiaries in the USA and Spain, and also includes Akern S.r.l. (bioimpedance analysis) and Athletica Cetilar S.r.l. (sports medicine).

PharmanutraGroup.com Pharmanutra.it

For further information:

Via Campodavela 1 - 56122 Pisa

Tel. +39 050 7846500

investorrelation@pharmanutra.it Ufficio Stampa Interno press@calabughi.com

Via Santa Radegonda, 16 - 20121 Milano Tel. +39 02 83635708

Matteo Russo mrusso@sprianocommunication.com Cristina Tronconi ctronconi@sprianocommunication.com